ATAI Life Sciences NV
NASDAQ:ATAI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ATAI Life Sciences NV
Operating Expenses
ATAI Life Sciences NV
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Operating Expenses
-$115.4m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Operating Expenses
-€20.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
|
Merck KGaA
XETRA:MRK
|
Operating Expenses
-€8.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-2%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Operating Expenses
-€1.2m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Operating Expenses
-€538.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Operating Expenses
-€26m
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
ATAI Life Sciences NV
Glance View
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company is headquartered in Berlin, Berlin and currently employs 81 full-time employees. The company went IPO on 2021-06-18. The firm is aiming to transform the treatment of mental health disorders.
See Also
What is ATAI Life Sciences NV's Operating Expenses?
Operating Expenses
-115.4m
USD
Based on the financial report for Dec 31, 2025, ATAI Life Sciences NV's Operating Expenses amounts to -115.4m USD.
What is ATAI Life Sciences NV's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-5%
Over the last year, the Operating Expenses growth was -15%. The average annual Operating Expenses growth rates for ATAI Life Sciences NV have been 7% over the past three years , -5% over the past five years .